Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

cybin deal

Finance

11 Dec 2023

Tryp Therapeutics To Be Acquired by Exopharm

Tryp Therapeutics announces signing of definitive agreement with Exopharm Limited....

By Microdose NewsDesk
patent

Industry

6 Dec 2023

Cybin Granted U.S. Patent For CYB003 Psilocybin Program

New patent provides IP protection until at least 2041. Cybin’s patent portfolio now includes 39 granted patents and over 170 pending applications....

By Microdose NewsDesk

Don’t Miss

4 Dec 2023

News You Might Have Missed: Dec 4th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Breaking News

30 Nov 2023

Cybin Reports Positive Topline Data from Phase 2 Study of Major Depressive Disorder

Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

27 Nov 2023

New Study Looks at Shame, Guilt and the Psychedelic Experience

A new study looks at emotionally painful, shame-related processes with psychedelic use....

By Microdose NewsDesk

Finance

24 Nov 2023

Filament Health Announces US$14.4 million Funding & Planned NASDAQ Listing

Filament Health has signed a non-binding term sheet for up to US$14.4 million in funding through a convertible note....

By Microdose NewsDesk
news psychedelic

Don’t Miss

20 Nov 2023

News You Might Have Missed: Nov 20th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Breaking News

26 Oct 2023

Breaking News: Beckley Waves Acquires Nue Life

In breaking news, Beckley Waves announces the acquisition of Nue Life....

By Microdose NewsDesk
DMT

Uncategorized

25 Oct 2023

Cybin Granted Two New Patents For DMT Program

Cybin has added to this growing IP portfolio with the granting of two more patents for its DMT program....

By Microdose NewsDesk

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.